Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO, suspends its shares

Hong Kong’s Securities and Futures Commission (SFC) has directed the stock exchange to suspend trading of US-based biotech firm Cloudbreak Pharma pending an investigation into its US$78 million initial public offering (IPO) last year.
“The SFC has serious concerns that Cloudbreak’s initial public offering may have been rigged to create an artificial impression of demand for Cloudbreak’s shares,” the SFC said in a statement on Thursday.
The regulator considered the suspension “necessary or...